MBA STRATEGIC MANAGEMENT. Aravind Eye Care System. 

Scene 1

Strategic Analysis: Market Entry · Digital Transformation Competitive Threats · Diversification

SWOT  ·  PESTEL  ·  Porter's Five Forces  ·  Strategic Options  ·  Recommendations

Submitted By :- Archi Gupta (2552022) Manya Munjal (2552063) Kanishka Sharma (2552053) Divyanshi Jindal (2552039) Isha Manisha Tirkey (2552047) Anushka (2552021)

Case Overview. Company Profile & Industry Context. 

Scene 2

Aravind Eye Care System  |  Strategic Management Case Study

Founded 1976 by Dr. G. Venkataswamy, Madurai 15 hospitals across 6 states in India ~4.9M outpatients & 580K+ surgeries/year 50% patients treated FREE via cross-subsidy Aurolab: IOL manufacturing wing (est. 1992) LAICO: Training institute for global replication Revenue ~₹800 Cr; operationally self-sustaining

Global eye care market: $90B+ (2024), growing 5.5% CAGR India: 8M+ blind; 80% cases preventable/treatable Telemedicine in ophthalmology growing post-COVID Private hospital chains entering tier-2/3 cities Govt push: National Blindness Control Programme AI diagnostics disrupting traditional screening Growing medical tourism: eye care in SE Asia & Africa

Core Strategic Problem. The Four-Dimensional Strategic Challenge. 

Scene 3

Vast unserved rural & international markets exist. How should Aravind scale geographically without compromising quality or mission?

AI, telemedicine, and digital diagnostics are reshaping eye care. Aravind risks falling behind if it does not adopt these technologies strategically.

Corporate hospital chains (LVPEI, Dr. Agarwals, Vasan) are aggressively expanding into Aravind's core geographies and patient segments.

Over-reliance on cataract surgery (~70% revenue). New eye conditions, retina care, paediatric ophthalmology offer growth — but require new capabilities.

PESTEL Analysis. Macro-Environmental Factors Impacting Aravind. 

Scene 4

Macro-Environmental Factors Impacting Aravind

Govt support via NBCP & Ayushman Bharat; regulatory changes in telemedicine; export controls on medical devices.

Rising middle class affords private care; rural income growth; rupee volatility affects Aurolab exports; inflation in equipment costs.

Ageing population = rising cataract demand; low eye-care awareness in rural India; health literacy improving via digital media.

AI diagnostics, telemedicine, robotic surgery; digital health records; low-cost smartphone-based screening tools.

Solar-powered vision centres; sustainable procurement; climate risk to rural camp logistics; ESG reporting pressure.

Medical device regulations (MDR 2017); data privacy (DPDP Act); FSSAI norms; IP protection for Aurolab patents.

Porter's Five Forces. Competitive Intensity in Indian Eye Care. 

Scene 5

Corporate chains expanding (Dr. Agarwals, Vasan) Low capital barrier for small clinics Brand & trust = Aravind's moat

No substitute for cataract surgery Traditional healers declining Pharma alternatives limited

Aurolab = self-supply of IOLs Multiple equipment vendors Negotiating leverage at scale

Free patients have zero power Paying patients have choice Urban segment price-sensitive

SWOT Analysis. Internal Capabilities vs. External Environment. 

Scene 6

Internal Capabilities vs. External Environment

Self-sustaining cross-subsidy model Aurolab: $2 IOL — 98% cost reduction LAICO global training & brand equity 2,000+ surgeries/surgeon/yr — 10× avg Trusted brand in rural/semi-urban India Operational SOPs with McDonald's efficiency

70%+ revenue from cataract — single-service risk Limited digital infrastructure in rural centres Slow urban expansion strategy Leadership succession post-Dr. V era Thin margins constrain R&D investment Limited marketing/brand presence in metro cities

AI screening & telemedicine at village level Expand Aurolab to retinal/glaucoma devices International market entry: Africa, SE Asia Govt NBCP & Ayushman Bharat partnerships Paediatric ophthalmology — untapped segment Medical tourism from global diaspora

Dr. Agarwals, Vasan, LVPEI rapid expansion VC-funded digital eye care startups (iCare, etc.) Govt policy changes on medical device pricing AI diagnostics commoditising basic screening Loss of key clinical talent to corporate hospitals Replication of cross-subsidy model by competitors

Key Strategic Insights. What the Frameworks Tell Us — The 'So What?'. 

Scene 7

What the Frameworks Tell Us — The 'So What?'

Aravind's cost structure is unmatched — but it is concentrated in cataract. Competitors need only to match it in one specialty to threaten significant revenue.

PESTEL and Five Forces both signal technology disruption is imminent. AI screening startups can disintermediate Aravind's outreach model within 5 years if not preempted.

Manufacturing capability in IOLs is proven. Extending to retinal implants, glaucoma shunts, and diagnostic devices is a natural adjacency with massive export potential.

Africa and SE Asia have the same blindness burden as India in 1976. A hub-and-spoke model export — starting with LAICO-trained local partners — can replicate the India story.

In an era of ESG and social impact investing, Aravind's brand is investable. It can attract capital that for-profit competitors cannot — if it builds investor-grade reporting.

Strategic Option 1. Digital-First Transformation: AI + Telemedicine Platform. 

Scene 8

Digital-First Transformation: AI + Telemedicine Platform

Build a proprietary AI-powered eye screening and telemedicine platform — 'AravindConnect' — deployed across all vision centres and mobile units to dramatically extend reach.

10× outreach at 20% of current cost per patient Real-time data for clinical quality monitoring Defensible first-mover advantage vs. startups Monetisable B2B SaaS — sell to other hospitals Supports WHO global vision goals partnership

₹150–200 Cr upfront tech investment required Rural connectivity remains a significant gap Requires new talent: data scientists, product managers Risk of mission drift — tech ≠ surgery capacity Data privacy regulations add compliance burden

Slide 8 of 15  |  Option 1: Digital Transformation

Strategic Option 2. International Market Entry: Africa & South-East Asia. 

Scene 9

International Market Entry: Africa & South-East Asia

Establish Aravind-model eye care hubs in 3 high-burden African and SE Asian countries using LAICO-trained local partners and Aurolab supply chain within 5 years.

Ethiopia (5M+ visually impaired) Kenya / East Africa hub Bangladesh & Myanmar Vietnam (eye care deficit) Nigeria (largest African market)

Replicate proven model in similar context Aurolab gains new export markets LAICO training creates brand goodwill WHO & global health fund partnerships Diversifies India-concentration risk

Political/regulatory risk in new markets High capital for hospital infrastructure Cultural & language barriers Core India mission may be under-resourced Long gestation period: 7–10 years to break even

Strategic Option 3. Service Diversification: Beyond Cataract. 

Scene 10

Expand Aravind's clinical portfolio into retina, glaucoma, paediatric ophthalmology, and cornea — supported by new Aurolab device categories and retraining of surgical staff.

Diabetic retinopathy cases rising 9% CAGR. Aurolab can develop retinal implants. 40M+ diabetics in India are at risk.

Chronic disease with recurring revenue. Drainage devices within Aurolab's manufacturing reach. Growing elderly population.

Refractive errors in children — massive unmet need. School screening programme already in place. Natural extension.

Complex surgery requiring donor networks. Requires separate supply chain. Longer learning curve for Aurolab.

Slide 10 of 15  |  Option 3: Diversification

Options Comparison Matrix. Evaluating the Three Strategic Options. 

Scene 11

Criterion Option 1: Digital Option 2: Market Entry Option 3: Diversification Mission Alignment ★★★★★ ★★★★★ ★★★★☆ Financial Feasibility ★★★☆☆ ★★☆☆☆ ★★★★☆ Speed to Impact ★★★★☆ ★★☆☆☆ ★★★☆☆ Competitive Advantage ★★★★★ ★★★★☆ ★★★☆☆ Risk Level Medium High Low–Medium Capex Required ₹150–200 Cr ₹400–600 Cr ₹100–150 Cr Time to ROI 3–5 years 7–10 years 4–6 years Recommended? ✔ YES ✔ Phase 2 ✔ YES

Scale of Impact. Patient Reach — Free vs Paid (Annual, in Millions). 

Scene 12

Patient Reach — Free vs Paid (Annual, in Millions)

Note: 2020 dip reflects COVID-19 disruption. Data sourced from Aravind Annual Reports.

FINAL RECOMMENDATION. A Phased Integrated Strategy. 

Scene 13

Launch AravindConnect AI platform. Pilot retina & paediatric services in 3 hospitals. Aurolab R&D for retinal devices.

Roll out digital platform to all vision centres. Expand new specialties to all 15 hospitals. Generate surplus for international fund.

Launch in 2 African & 1 SE Asian market via LAICO-partner franchise model. Aurolab becomes global supplier.

Expected Outcomes. Projected Impact by Phase — 7-Year Horizon. 

Scene 14

Projected Impact by Phase — 7-Year Horizon

Implementation Plan. Roadmap, Risks & Mitigation. 

Scene 15

Hire 50 tech/data talent; partner with IIT Madras AI lab Pilot AravindConnect in 50 vision centres Launch retina & paediatric OPD in 3 flagship hospitals Aurolab R&D team for retinal device prototyping

Scale AravindConnect to all 400+ vision centres Train 200 retina surgeons via LAICO Launch Aurolab retinal device commercially Establish international partnerships in Kenya & Ethiopia

Open 3 Aravind-model hospitals in Africa/SE Asia Aurolab becomes preferred global supplier in 10 countries List Aurolab as independent social enterprise (partial IPO) Establish Aravind Global Foundation

30M patients, 5 countries, ₹3,000 Cr revenue

The Strategic Imperative. 1. Aravind's cross-subsidy model is a proven, self-sustaining engine — the strategic task is to extend it, not replace it.. 

Scene 16

Aravind's cross-subsidy model is a proven, self-sustaining engine — the strategic task is to extend it, not replace it.

Digital transformation (AravindConnect) is the most urgent priority — it defends against startups and creates a new revenue stream.

Diversification into retina and paediatric care reduces single-service risk and aligns with India's growing chronic disease burden.

International market entry is the highest-impact long-term move — but must be sequenced after domestic platform is built.

Mission and growth are not trade-offs. The recommended strategy grows revenue 4× while protecting the 50% free-patient commitment.

"Voluminous, sustainable, quality eye care for all — regardless of ability to pay."  — Dr. Venkataswamy

Untitled design

Scene 1 (0s)

Scene 2 (17s)

Scene 3 (53s)

Scene 4 (1m 26s)

Scene 5 (2m 6s)

Scene 6 (2m 34s)

Scene 7 (3m 20s)

Scene 8 (4m 8s)

Scene 9 (4m 40s)

Scene 10 (5m 16s)

Scene 11 (6m 1s)

Scene 12 (6m 23s)

Scene 13 (6m 38s)

Scene 14 (7m 5s)

Scene 15 (7m 33s)

Scene 16 (8m 11s)